Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Pasireotide
Drug ID BADD_D01684
Description Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.
Indications and Usage For the treatment of Cushing’s disease, specifically for those patients whom pituitary surgery has not been curative or is not an option.
Marketing Status Not Available
ATC Code H01CB05
DrugBank ID DB06663
KEGG ID D10147
MeSH ID C517782
PubChem ID 9941444
TTD Drug ID D0TV0C
NDC Product Code 0078-0634; 71161-126; 0078-0643; 55292-143; 71161-130; 55292-142; 55292-139; 0078-0642; 0078-0741; 55292-141; 55292-132; 0078-0633; 0078-0748; 55292-140; 55292-131; 71161-129; 55292-133; 0078-0635; 0078-0641; 71161-127; 71161-128
Synonyms pasireotide | cyclo((4R)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-d-tryptophyl-L-lysyl-4-o-benzyl-L-tyrosyl-L-phenylalanyl-) | SOM-230 | SOM 230 | SOM230
Chemical Information
Molecular Formula C58H66N10O9
CAS Registry Number 396091-73-9
SMILES C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4 )OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pollakiuria20.02.02.0070.003921%
Polydipsia05.03.03.002; 14.05.02.0010.007841%Not Available
Polyuria20.02.03.0020.013722%Not Available
Prothrombin level increased13.01.02.011--Not Available
Pruritus23.03.12.001--
Pyrexia08.05.02.0030.005881%
Rash23.03.13.001--Not Available
Renal failure20.01.03.0050.001534%Not Available
Sepsis11.01.11.0030.001534%
Sinus bradycardia02.03.03.009--
Somnolence19.02.05.003; 17.02.04.0060.005881%
Syncope24.06.02.012; 17.02.04.008; 02.01.02.0080.003921%
Tachycardia02.03.02.0070.003921%Not Available
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.0070.007841%
Visual impairment06.02.06.0080.003921%Not Available
Vitamin D deficiency14.12.03.0030.003921%Not Available
Vomiting07.01.07.0030.025483%
Weight decreased13.15.01.0050.021563%
Malignant neoplasm progression16.16.01.0050.003068%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Haemorrhage24.07.01.002--Not Available
Hepatic enzyme increased13.03.01.0190.005881%Not Available
Decreased appetite14.03.01.005; 08.01.09.0280.015682%
Type 2 diabetes mellitus14.06.01.003; 05.06.01.0030.011762%Not Available
Cortisol free urine increased13.10.09.0110.005881%Not Available
Concomitant disease progression08.01.03.0640.001023%Not Available
Insulin-like growth factor increased13.10.10.0040.003921%Not Available
Glucocorticoid deficiency14.11.01.037; 05.01.02.0110.003921%Not Available
Hyperosmolar hyperglycaemic state14.07.04.006; 17.02.04.020; 05.07.04.0060.003921%Not Available
The 4th Page    First    Pre   4    Total 4 Pages